Exelixis, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Exelixis, Inc. (EXEL) holds an ST Score of 57.3 out of 100 (B-), with its strongest factor being Profitability (A+) and its weakest Valuation (F). Analysts rate EXEL Hold across 33 ratings with a $51.78 average price target (-0.1% vs the current $58.36).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- MomentumA+
- GrowthA-
- ForecastC
- Financial StrengthD
- ValuationF
- Piotroski7/9
Contact
EXEL stock: frequently asked questions
What is EXEL's ST Score?
Exelixis, Inc. (EXEL) has an ST Score of 57.3 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is EXEL a buy, sell, or hold?
Wall Street's consensus rating on EXEL is Hold based on 33 analyst ratings. Our own ST Score grades it B- (57.3/100). This is data, not investment advice — always do your own research.
What is EXEL's valuation grade?
Exelixis, Inc. (EXEL) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is EXEL's growth grade?
Exelixis, Inc. (EXEL) earns a growth grade of A-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is EXEL's profitability grade?
Exelixis, Inc. (EXEL) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is EXEL's financial strength grade?
Exelixis, Inc. (EXEL) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for EXEL?
The average analyst price target for Exelixis, Inc. (EXEL) is $51.78 from 33 analysts, which is -0.1% versus the recent price of $58.36.
What is EXEL's Piotroski score?
Exelixis, Inc. (EXEL) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.